Malla A, Williams R, Kopala L, Smith G, Talling D, Balshaw R
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Acta Psychiatr Scand Suppl. 2006(430):22-8. doi: 10.1111/j.1600-0447.2006.00758.x.
To examine changes in subjective and objective dimensions of quality of life (QoL) in a large Canadian sample of patients with diagnosis of schizophrenia or schizoaffective disorder treated in academic and non-academic settings over a 2-year period.
Patients recruited in the study across the country were assessed for QoL and functioning using the Client and Provider versions of the Wisconsin Quality of Life Questionnaire (WQoL) and the Short Form-36 (SF-36) at baseline (n = 448), 1 year (n = 308-353) and 2 years (188-297). Data were analyzed to examine change across time using multivariate analyses controlling for potential influence of variables such as age, regional variation, gender, duration of illness, type of treatment taken and baseline measures of symptoms and QoL.
The weighted quality of life index (W-QoL-I) showed a significant change on both the client and the provider versions of the WQoL while the physical and mental composites of the SF-36 showed change only at 2 years. These changes were influenced significantly by baseline scores on W-QoL-I and in the case of provider version of the WQoL by baseline Brief Psychiatric Rating Scale (BPRS) scores. Regional variation or type of medication had no impact on improvement in QoL.
Within a naturalistic sample of schizophrenia patients treated and followed in routine care the overall QoL showed an improvement over time but this improvement was not influenced by the type of medication prescribed.
在一个大型加拿大样本中,考察在学术和非学术环境中接受治疗的、诊断为精神分裂症或分裂情感性障碍的患者,其生活质量(QoL)主观和客观维度在两年期间的变化。
在全国范围内招募的研究患者,在基线期(n = 448)、1年(n = 308 - 353)和2年(188 - 297)时,使用威斯康星生活质量问卷(WQoL)的患者版和提供者版以及简明健康状况调查量表(SF - 36)对生活质量和功能进行评估。使用多变量分析来检验随时间的变化,控制诸如年龄、地区差异、性别、病程、所接受治疗类型以及症状和生活质量的基线测量等变量的潜在影响。
生活质量加权指数(W - QoL - I)在WQoL的患者版和提供者版上均显示出显著变化,而SF - 36的身体和心理综合指标仅在2年时显示出变化。这些变化受到W - QoL - I基线分数的显著影响,在WQoL提供者版的情况下,还受到基线简明精神病评定量表(BPRS)分数的影响。地区差异或药物类型对生活质量的改善没有影响。
在接受常规治疗和随访的精神分裂症患者的自然样本中,总体生活质量随时间有所改善,但这种改善不受所开药物类型的影响。